Market capitalization | $45.54m |
Enterprise Value | $-7.82m |
P/E (TTM) P/E ratio | negative |
EV/Sales (TTM) EV/Sales | -0.91 |
P/S ratio (TTM) P/S ratio | 5.31 |
P/B ratio (TTM) P/B ratio | 0.78 |
Revenue growth (TTM) Revenue growth | -93.70% |
Revenue (TTM) Revenue | $8.57m |
EBIT (operating result TTM) EBIT | $-52.13m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
6 Analysts have issued a SCYNEXIS, Inc. forecast:
6 Analysts have issued a SCYNEXIS, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 8.57 8.57 |
94%
94%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -52 -52 |
170%
170%
|
EBIT (Operating Income) EBIT | -52 -52 |
171%
171%
|
Net Profit | -36 -36 |
150%
150%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
Head office | United States |
CEO | David Gonzalez |
Employees | 29 |
Founded | 1999 |
Website | www.scynexis.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.